Bioluminescence Ventures

GEMMABio is a therapeutics company focused on developing gene therapies for individuals living with rare diseases, aiming to enhance global access to advanced treatments. he company's mission includes improving research speed and global accessibility of life-changing therapies for patients in need.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Nido Biosciences, Inc., incorporated in 2018 and based in Boston, Massachusetts, is a clinical-stage company focused on developing precision medicines for severe neurological diseases. The company employs a functional genomics discovery platform utilizing human cell lines to identify novel therapeutic targets for various neuromuscular and neurodegenerative conditions. By leveraging advances in neuroscience and human genetics, Nido Biosciences aims to create precise medications that address the underlying biology of these diseases, ultimately restoring healthy cell function and improving patient outcomes.